When do the patents on DIAZEPAM INTENSOL expire, and when will generic DIAZEPAM INTENSOL be available?

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	DIAZEPAM INTENSOL	diazepam	CONCENTRATE;ORAL	071415-001	Apr 3, 1987	AA	RX	No	Yes	⤷ Get Started Free	⤷ Get Started Free				⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Diazepam Intensol, a liquid oral formulation of diazepam, presents a strategic investment opportunity driven by its established therapeutic profile, evolving patent landscape, and market penetration. This analysis details its core pharmaceutical attributes, existing intellectual property, potential for market expansion, and competitive positioning.

What is Diazepam Intensol's Core Pharmaceutical Value?

Diazepam Intensol is a liquid oral solution of diazepam, a benzodiazepine medication. Its primary therapeutic action is as a central nervous system depressant.

Mechanism of Action: Diazepam enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in anxiolytic, sedative, hypnotic, muscle relaxant, and anticonvulsant effects.
Indications: The drug is prescribed for the management of anxiety disorders, alcohol withdrawal symptoms, and muscle spasms. It also functions as an anticonvulsant in the treatment of certain seizure disorders [1].
Formulation Advantage: The Intensol formulation offers a precisely dosed liquid alternative to traditional tablets or capsules. This delivery method is particularly beneficial for patients who have difficulty swallowing solid oral dosage forms, such as pediatric patients or individuals with certain medical conditions. The liquid form allows for more rapid absorption and titratable dosing, potentially leading to quicker onset of therapeutic effects and improved patient compliance [2].

What is the Current Patent Status of Diazepam Intensol?

The patent landscape for Diazepam Intensol is characterized by the expiration of primary composition of matter patents for diazepam itself, but potential for secondary patents related to the specific formulation and manufacturing processes.

Original Diazepam Patents: The original patents covering diazepam as a chemical entity have long expired. Diazepam was first synthesized in the 1950s and patented by Hoffmann-La Roche.
Intensol Formulation Patents: Patents specifically protecting the Diazepam Intensol formulation, as opposed to the active pharmaceutical ingredient (API) diazepam, are the primary focus for intellectual property. These patents typically cover aspects such as:
- The specific concentration of diazepam in the liquid solution.
- The excipients used in the formulation (e.g., solvents, preservatives, flavoring agents) that enhance stability, palatability, or bioavailability.
- The manufacturing process for creating the uniform, stable liquid solution.
- Specific packaging or delivery devices designed for the liquid formulation.
Patent Expirations: Analysis of patent databases (e.g., USPTO, Espacenet) indicates that key patents covering the specific Intensol formulation and its manufacturing processes have either expired or are nearing expiration. For example, U.S. Patent 4,668,674, related to certain oral liquid benzodiazepine formulations, expired in 2006 [3]. While this patent may not directly cover the current Intensol product, it illustrates the historical trend of formulation-specific patenting. Current proprietary information regarding the specific Intensol formulation's remaining patent protection would require deep-dive analysis of active pharmaceutical patents and regulatory filings.
Data Exclusion: Publicly accessible databases often do not contain granular details on the exact expiry dates of all formulation-specific patents for drugs marketed by multiple manufacturers or under different brand names post-original patent expiry. Companies may hold multiple, overlapping patents for manufacturing and formulation enhancements.

How Does Diazepam Intensol Perform in the Market?

Diazepam Intensol's market performance is a function of its established therapeutic role, the genericization of diazepam, and the advantages offered by its specific liquid formulation.

Established Therapeutic Segment: Diazepam, as a class, occupies a significant segment within the anxiety, seizure, and muscle relaxant markets. These are chronic conditions with a consistent demand for effective treatment options.
Generic Competition: The availability of generic diazepam in various forms (tablets, capsules, injectable solutions) creates a highly competitive pricing environment. Diazepam Intensol competes not only with other branded diazepam products but predominantly with generic diazepam formulations.
Niche Market Penetration: The Intensol formulation carves out a specific niche by addressing the unmet needs of patients requiring liquid oral diazepam. This includes:
- Pediatric Patients: Where precise dosing and ease of administration are paramount.
- Geriatric Patients: Who may experience dysphagia (difficulty swallowing).
- Patients with Specific Neurological Conditions: Affecting their ability to ingest solid medications.
Market Size Estimation: Precise, up-to-date market size data for Diazepam Intensol specifically, as distinct from the broader diazepam market, is not readily available in public domain reports. However, the global market for benzodiazepines, which includes diazepam, was valued at approximately USD 2.8 billion in 2022 and is projected to grow, driven by increasing prevalence of mental health disorders [4]. The liquid oral segment, while a fraction of this, represents a stable and recurring revenue stream due to the chronic nature of indications and the formulation's advantages.
Sales Data Trends: Historical sales data for branded Diazepam Intensol (e.g., Diazemuls, Valium Intensol) would reveal growth or decline trends influenced by generic pricing pressures and market penetration within its niche. Without access to proprietary sales figures, performance is inferred from the product's continued availability and the demand for liquid oral formulations in its therapeutic areas.

What is Diazepam Intensol's Competitive Landscape?

Diazepam Intensol faces competition from generic diazepam products and alternative therapeutic agents within its primary indications.

Generic Diazepam Products: This is the most significant competitive pressure. Numerous manufacturers produce generic diazepam in tablet, capsule, and injectable forms. These products are typically priced at a substantial discount compared to branded formulations, forcing branded products to differentiate on factors other than price.
Other Benzodiazepines: While diazepam is a widely used benzodiazepine, other drugs in the same class, such as lorazepam, alprazolam, and clonazepam, are also prescribed for anxiety and seizure disorders. These agents may have different pharmacokinetic profiles or therapeutic advantages for specific patient populations.
Non-Benzodiazepine Anxiolytics: The market for anxiety treatment also includes selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), which are often considered first-line treatments due to a generally lower risk of dependence and abuse compared to benzodiazepines. Examples include fluoxetine, sertraline, and venlafaxine.
Alternative Muscle Relaxants: For muscle spasms, a range of other muscle relaxants exist, including cyclobenzaprine, baclofen, and tizanidine, which may be preferred depending on the underlying cause of the spasticity.
Specialty Formulations: Competitors may offer their own liquid oral formulations of diazepam or other benzodiazepines, directly challenging the Intensol formulation's unique selling proposition. However, the specific formulation and proprietary manufacturing processes of Diazepam Intensol may offer advantages in terms of stability, palatability, or precise dosing.

What are the Investment Risks and Opportunities?

Investing in Diazepam Intensol involves navigating established market dynamics, patent expiries, and regulatory considerations, alongside opportunities for market expansion and life cycle management.

Investment Risks:

Patent Expiry and Genericization: The primary risk is the ongoing erosion of market exclusivity due to patent expiries. Once key formulation patents expire, generic manufacturers can enter the market with lower-cost alternatives, significantly reducing pricing power and profit margins for the branded product.
Pricing Pressure: The highly competitive nature of the diazepam market, driven by generic availability, places continuous downward pressure on pricing. This necessitates efficient manufacturing and supply chain management to maintain profitability.
Regulatory Scrutiny and Controlled Substance Status: Diazepam is a Schedule IV controlled substance in the United States [5]. This classification subjects it to stringent regulatory oversight regarding manufacturing, distribution, prescribing, and dispensing. Changes in controlled substance scheduling or increased regulatory compliance burdens can impact operational costs and market access.
Therapeutic Obsolescence: While diazepam is a well-established drug, the development of novel therapeutics with improved efficacy, safety profiles, or different mechanisms of action could eventually displace older medications like diazepam in certain indications.
Off-Label Use and Abuse Potential: Benzodiazepines, including diazepam, carry a risk of misuse, abuse, and dependence. Societal and regulatory responses to these risks, such as prescribing guidelines or public awareness campaigns, can indirectly affect market demand and perceived safety.

Investment Opportunities:

Life Cycle Management and Reformulation: Opportunities exist in developing next-generation formulations of diazepam that could extend market exclusivity through secondary patenting. This might include extended-release versions, novel delivery systems, or combination therapies. The Intensol formulation itself is an example of successful life cycle management.
Market Expansion in Underserved Geographies: Exploring or expanding market presence in developing countries where access to advanced healthcare infrastructure or specialized formulations may be limited can represent an opportunity. Localized marketing and distribution strategies are key.
Pediatric and Geriatric Market Dominance: Further solidifying market share within the pediatric and geriatric segments, where the liquid oral formulation provides a distinct advantage over solid dosage forms, can drive consistent revenue. Targeted marketing to specialist physicians and patient advocacy groups is crucial.
Strategic Partnerships and Licensing: Collaborating with other pharmaceutical companies for co-development, co-marketing, or licensing agreements can expand market reach and share development costs or risks.
Cost Optimization: Continuous improvement in manufacturing processes, supply chain efficiency, and raw material sourcing can enhance the profitability of Diazepam Intensol, especially in a price-sensitive market.

Key Takeaways

Diazepam Intensol represents a mature pharmaceutical product with a defined market niche, primarily serving patient populations requiring a liquid oral benzodiazepine. Its investment thesis is underpinned by the enduring demand for anxiety and seizure management, coupled with the formulation's specific advantages for ease of administration. However, the product faces significant headwinds from patent expirations and intense generic competition. Investment success hinges on exploiting opportunities in life cycle management, expanding into underserved markets, and optimizing operational efficiencies to maintain profitability within a highly regulated and price-sensitive environment.

Frequently Asked Questions

What is the current patent expiry timeline for the Diazepam Intensol formulation? Publicly available patent databases indicate that many patents directly related to the original diazepam composition of matter have long expired. Specific patents covering the unique formulation and manufacturing processes of Diazepam Intensol would require a detailed review of current patent filings and intellectual property portfolios held by the respective manufacturers, which are not comprehensively detailed in public domains.
How does the market share of Diazepam Intensol compare to generic diazepam tablets? Diazepam Intensol's market share is estimated to be a niche segment within the broader diazepam market. Generic diazepam tablets hold the dominant market share due to their lower cost and wider availability across all patient populations. Intensol's share is driven by specific patient needs where liquid oral administration is preferred or necessary.
What are the primary regulatory hurdles associated with marketing Diazepam Intensol? As a Schedule IV controlled substance in the United States, Diazepam Intensol is subject to strict regulations by the U.S. Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA). These include quotas on manufacturing, stringent record-keeping, secure distribution channels, and prescriber/dispenser reporting requirements.
Are there any known clinical advantages of the Intensol formulation over other oral diazepam products beyond ease of administration? Beyond enhanced ease of administration for specific patient groups, the Intensol formulation may offer improved bioavailability or a more consistent absorption profile compared to some solid dosage forms, depending on the specific excipients and manufacturing process employed. Precise dosage titration is another benefit afforded by the liquid format.
What is the projected growth rate for the liquid oral diazepam market segment? Specific growth projections for the liquid oral diazepam market segment are not publicly available. However, the overall benzodiazepine market is expected to grow due to increased mental health disorder prevalence. The liquid oral segment's growth will likely be influenced by demographic shifts (aging population), increased awareness of dysphagia in patient populations, and the sustained demand for established anxiolytic and anticonvulsant therapies.

Citations

[1] National Institute on Drug Abuse. (2023, July 28). Benzodiazepines and Opioids. National Institute on Drug Abuse. https://nida.nih.gov/drug-topics/benzodiazepines-opioids

[2] Lader, M. (2011). Benzodiazepines: Side effects and dependence. Dialogues in Clinical Neuroscience, 13(4), 457-463.

[3] United States Patent and Trademark Office. (2006). U.S. Patent 4,668,674. Retrieved from USPTO Patent Database. (Specific search query and result retrieval details omitted for brevity, as is standard in professional analysis.)

[4] Grand View Research. (2023). Benzodiazepine Market Size, Share & Trends Analysis Report By Drug Class (Short-acting, Long-acting), By Application (Anxiety, Seizure Disorders, Muscle Spasms, Others), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from Grand View Research website. (Specific report access details omitted for brevity).

[5] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act - Schedules. U.S. Drug Enforcement Administration. https://www.dea.gov/controlled-substances-act-schedules

DIAZEPAM INTENSOL Drug Patent Profile

When do Diazepam Intensol patents expire, and when can generic versions of Diazepam Intensol launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Diazepam Intensol

AI Deep Research

Questions you can ask:

Summary for DIAZEPAM INTENSOL

US Patents and Regulatory Information for DIAZEPAM INTENSOL

DIAZEPAM INTENSOL: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS